Article Information
History
- January 10, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Stephen Ahn, M.D.Ph.D.1,
- Jae-Sung Park, M.D.1,
- Heewon Kim2,
- Minkyu Heo2,
- Young Chul Sung2 and
- Sin-Soo Jeun, M.D. Ph.D1,*
- 1Department of Neurosurgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- 2Genexine, Inc., Seongnam-si, Gyeonggi-do, South Korea
- ↵*Address correspondence to:
Sin-Soo Jeun, M.D. Ph.D. Department of Neurosurgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodae-ro, Seocho-gu, Seoul, South Korea 06591, Tel.: +82-2-2258-7535, Fax: +82-2-2258-1853, E-mail: ssjeun{at}catholic.ac.kr
Posted January 10, 2022.
Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma
